Longitudinal Single Case Report: Intravenous Therapeutic Plasma Secretome Therapy in a Parkinson's Patient with Vascular Comorbidities

Abstract

Background: Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons, resulting in a complex combination of motor and non-motor symptoms. Conventional therapies such as levodopa are primarily symptomatic and often lead to long-term complications, highlighting the need for alternative approaches capable of modifying disease progression. Objective: This case report aims to evaluate the short-term clinical effects of a single session of cell rejuvenation therapy using Hematopoietic Stem Cell (HSC)-based Therapeutic Plasma Secretome (TPS) in a Parkinson’s patient with vascular comorbidities. Methodology: A 71-year-old male diagnosed with Parkinson’s disease and a history of mild stroke received TPS therapy via intravenous infusion at a dose of 1 million cells/kg body weight, prepared at a BPOM-certified facility. Functional evaluation was conducted longitudinally using the UPDRS-8 scale over a four-week period. Results: The UPDRS-8 score improved from 8 to 6, accompanied by clinical improvements including increased walking speed, resolution of tremors, and enhanced independence in daily activities. No significant adverse effects were observed during the monitoring period. Conclusion: These preliminary findings support the potential of HSC-based TPS as a safe and promising non-invasive therapy for improving motor function in Parkinson’s patients. However, as a single case report lacking a control group and with a limited observation period, the results cannot yet be generalized. Further research through controlled clinical trials, long-term monitoring, and the development of reliable biomarkers is necessary to verify the efficacy and safety of this therapy.